It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
A veteran in cell therapy and oncology commercialisation
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
